Results 251 to 260 of about 436,330 (367)

Factors associated of long-term retention rate of Janus kinase inhibitors in a multi-failure rheumatoid arthritis population

, 2023
Marco Sebastiani, Alen Zabotti, Bruno Biasi, Sofia Cacioppo, Gilda Sandri, Ivan Giovannini, Andreina Manfredi, Luca Quartuccio   +7 more
openalex   +2 more sources

Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review

British Journal of Haematology, EarlyView.
Summary VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an X‐linked, systemic, haemato‐inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms,
Fieke W. Hoff, Roochi Trikha, Emma M. Groarke, Bhavisha A. Patel   +3 more
wiley   +1 more source

Differential response to Janus kinase inhibitors in refractory livedoid vasculopathy: Biomarker-guided therapy may improve clinical response. [PDF]

JAAD Int
Yu G, Zhu J, Zhang Y, Yang F, Yang J, Tao J.   +5 more
europepmc   +1 more source

Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis [PDF]

, 2013
Huaming Tan, Pankaj Gupta, Jane Harness, Robert Wołk, Sunny Chapel, Alan Menter, Bruce Strober, RG Langley, S. Krishnaswami, Kim Papp   +9 more
openalex   +1 more source

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

British Journal of Haematology, EarlyView.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny‐Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke, Mike Fischer, Florian H. Heidel, Tina M. Schnöder, Jörg P. Müller, Andreas Hochhaus, Sebastian Scholl   +12 more
wiley   +1 more source

Janus kinase inhibitors in localized scleroderma: a systematic literature review. [PDF]

Turk J Med Sci
Şener S, Şener YZ, Batu ED, Sari A, Akdoğan A.   +4 more
europepmc   +1 more source

Changes in NK Cells and Exhausted Th Cell Phenotype in RA Patients Treated with Janus Kinase Inhibitors: Implications for Adverse Effects [PDF]

Juan José Fernández-Cabero, Carmen Lasa-Teja, David San Segundo, Alejandra Comins‐Boo, Juan Irure‐Ventura, Daniel Rivera, J. L. Martín-Varillas, Cristina Mata, Montserrat Santos, Elena Aurrecoechea, Ricardo Blanco, Marcos López‐Hoyos   +11 more
openalex   +1 more source

Cytokine Milieu Relevant to Atopic Dermatitis Enhances Epidermal Trypsin‐Like Serine Protease Activity, Which Is Pharmacologically Suppressed in Human Keratinocytes

The Journal of Dermatology, EarlyView.
Shiori Onishi, Yohei Yasutomi, Onon Tsedendorj, Shin Morizane   +3 more
wiley   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Response to letter regarding 'Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis'. [PDF]

Ann Med
Yang H, An T, Zhang Q.
europepmc   +1 more source